Jacob Moyer, BS
Advertisement
Jacob Moyer, BS, is a graduate researcher at Mayo Clinic.
Articles by Jacob Moyer, BS
Jacob Moyer, BS, discusses early, real-world efficacy and safety data with nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive bladder cancer.
Advertisement
Latest Updated Articles
Moyer on Early Efficacy Data With Nadofaragene Firadenovec in BCG-Unresponsive NMIBCPublished: March 19th 2025 | Updated:
Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPHPublished: May 1st 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5